CL2014001244A1 - Uso de una composicion farmaceutica que comprende un derivado de 4-pregenen-11beta-17-21-triol-3,20-diona para tratar una condicion ocular tal como presion intraocular elevada, glaucoma, uveitis, degeneracion macular, retinopatia diabetica, rosacea ocular, desprendimiento de retina, entre otras. - Google Patents
Uso de una composicion farmaceutica que comprende un derivado de 4-pregenen-11beta-17-21-triol-3,20-diona para tratar una condicion ocular tal como presion intraocular elevada, glaucoma, uveitis, degeneracion macular, retinopatia diabetica, rosacea ocular, desprendimiento de retina, entre otras.Info
- Publication number
- CL2014001244A1 CL2014001244A1 CL2014001244A CL2014001244A CL2014001244A1 CL 2014001244 A1 CL2014001244 A1 CL 2014001244A1 CL 2014001244 A CL2014001244 A CL 2014001244A CL 2014001244 A CL2014001244 A CL 2014001244A CL 2014001244 A1 CL2014001244 A1 CL 2014001244A1
- Authority
- CL
- Chile
- Prior art keywords
- ocular
- pregenen
- 11beta
- uveitis
- triol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161558775P | 2011-11-11 | 2011-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014001244A1 true CL2014001244A1 (es) | 2014-11-14 |
Family
ID=47179019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001244A CL2014001244A1 (es) | 2011-11-11 | 2014-05-12 | Uso de una composicion farmaceutica que comprende un derivado de 4-pregenen-11beta-17-21-triol-3,20-diona para tratar una condicion ocular tal como presion intraocular elevada, glaucoma, uveitis, degeneracion macular, retinopatia diabetica, rosacea ocular, desprendimiento de retina, entre otras. |
CL2014001243A CL2014001243A1 (es) | 2011-11-11 | 2014-05-12 | Compuestos derivados de 4-pregenen-11beta-17-21-triol-3,20-diona, moduladores de los receptores glucocorticoide o mineralocorticoide; composicion farmaceutica; metodo de tratamiento de condiciones oculares tales como ojo seco, blefaritis, rosacea ocular, uveitis y degeneracion macular entre otras. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001243A CL2014001243A1 (es) | 2011-11-11 | 2014-05-12 | Compuestos derivados de 4-pregenen-11beta-17-21-triol-3,20-diona, moduladores de los receptores glucocorticoide o mineralocorticoide; composicion farmaceutica; metodo de tratamiento de condiciones oculares tales como ojo seco, blefaritis, rosacea ocular, uveitis y degeneracion macular entre otras. |
Country Status (24)
Country | Link |
---|---|
US (7) | US8906892B2 (es) |
EP (2) | EP2776041A1 (es) |
JP (2) | JP6158201B2 (es) |
KR (2) | KR102049615B1 (es) |
CN (2) | CN104203247B (es) |
AR (1) | AR088846A1 (es) |
AU (3) | AU2012335590B2 (es) |
BR (2) | BR112014011341A2 (es) |
CA (3) | CA2855929C (es) |
CL (2) | CL2014001244A1 (es) |
CO (2) | CO6970598A2 (es) |
ES (1) | ES2806603T3 (es) |
HK (2) | HK1200367A1 (es) |
IL (2) | IL232535B (es) |
IN (2) | IN2014CN03919A (es) |
MX (3) | MX363669B (es) |
MY (2) | MY182222A (es) |
PH (2) | PH12014501078A1 (es) |
RU (2) | RU2683775C2 (es) |
SG (3) | SG11201402225RA (es) |
TW (1) | TWI584809B (es) |
UA (2) | UA116622C2 (es) |
WO (2) | WO2013071010A1 (es) |
ZA (2) | ZA201403431B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
UA116622C2 (uk) * | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
EA201500651A1 (ru) | 2012-12-18 | 2015-11-30 | Альмираль, С.А. | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
MX371012B (es) * | 2013-12-13 | 2020-01-10 | Allergan Inc | Formas polimórficas de un compuesto similar a un esteroide y métodos para la preparación y su uso. |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
KR20170120161A (ko) | 2015-03-05 | 2017-10-30 | 알러간, 인코포레이티드 | 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds) |
WO2018053321A1 (en) * | 2016-09-16 | 2018-03-22 | Kala Pharmaceuticals, Inc. | Particles, compositions, and methods for ophthalmic and/or other applications |
WO2019055028A1 (en) * | 2017-09-15 | 2019-03-21 | Kala Pharmaceuticals, Inc. | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS |
CN116023425B (zh) * | 2023-03-28 | 2023-06-20 | 南京师范大学 | 曲安西龙衍生物及其医药用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6605514A (es) * | 1966-04-25 | 1967-10-26 | ||
IT1056711B (it) * | 1967-04-01 | 1982-02-20 | Vismara F Spa | Derivati dell idrocortisone |
US3484436A (en) * | 1967-09-07 | 1969-12-16 | Syntex Corp | Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids |
GB1227992A (es) * | 1968-01-23 | 1971-04-15 | Koninklijke Gist Spiritus | |
US3693032A (en) | 1971-04-23 | 1972-09-19 | Ibm | Antisaturation technique for ttl circuits |
US3984544A (en) * | 1975-02-28 | 1976-10-05 | Schering Corporation | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor |
JPS52136157A (en) * | 1976-04-14 | 1977-11-14 | Taisho Pharmaceut Co Ltd | Preparation of steroid 17-esters |
JPS60994B2 (ja) * | 1976-07-26 | 1985-01-11 | 大正製薬株式会社 | プレグナン系化合物の17α―エステル類の製造法 |
DE2735110A1 (de) * | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
US4221787A (en) * | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
US4221778A (en) * | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
DE4025342A1 (de) * | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
CZ20021265A3 (cs) * | 1999-10-15 | 2003-02-12 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemis | Nové deriváty fusidové kyseliny |
US6395721B1 (en) | 2000-01-05 | 2002-05-28 | Leonard Bloom | Low potency unpreserved sterile topical corticosteroid compositions for dermatitis |
US20040097574A1 (en) * | 2002-08-29 | 2004-05-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP2005008596A (ja) * | 2003-06-20 | 2005-01-13 | Kobayashi Pharmaceut Co Ltd | 眼科用組成物 |
DK1755616T3 (da) * | 2004-04-08 | 2013-11-25 | Eye Co Pty Ltd | Behandling af ekssudativ retinopati med mineralkortikoider |
WO2006017347A2 (en) * | 2004-07-12 | 2006-02-16 | Allergan, Inc. | Opthalmic compositions and methods for treating ophthalmic conditions |
US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
US7687484B2 (en) * | 2006-05-25 | 2010-03-30 | Bodor Nicholas S | Transporter enhanced corticosteroid activity |
EP2322183B1 (en) | 2006-06-01 | 2014-10-22 | Santen SAS | Use of prodrugs for ocular intravitreous administration |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
JP2009053880A (ja) | 2007-08-27 | 2009-03-12 | Sony Broadband Solution Corp | 情報処理装置、ならびにcpuユニット |
US8524697B2 (en) * | 2007-12-21 | 2013-09-03 | Merck Sharp & Dohme Corp. | C20-C21 substituted glucocorticoid receptor agonists |
BRPI0914630A2 (pt) * | 2008-06-26 | 2019-09-24 | Anterios Inc | liberação dérmica |
UA116622C2 (uk) * | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
-
2012
- 2012-09-11 UA UAA201406244A patent/UA116622C2/uk unknown
- 2012-09-11 UA UAA201406457A patent/UA111867C2/uk unknown
- 2012-11-09 TW TW101141986A patent/TWI584809B/zh not_active IP Right Cessation
- 2012-11-09 US US13/673,623 patent/US8906892B2/en not_active Expired - Fee Related
- 2012-11-09 CA CA2855929A patent/CA2855929C/en not_active Expired - Fee Related
- 2012-11-09 US US13/673,074 patent/US8865691B2/en not_active Expired - Fee Related
- 2012-11-09 CA CA2991883A patent/CA2991883C/en not_active Expired - Fee Related
- 2012-11-09 CA CA2855290A patent/CA2855290C/en not_active Expired - Fee Related
- 2012-11-09 AU AU2012335590A patent/AU2012335590B2/en not_active Ceased
- 2012-11-09 BR BR112014011341A patent/BR112014011341A2/pt not_active Application Discontinuation
- 2012-11-09 BR BR112014011333A patent/BR112014011333B1/pt not_active IP Right Cessation
- 2012-11-09 MX MX2014005678A patent/MX363669B/es unknown
- 2012-11-09 JP JP2014541293A patent/JP6158201B2/ja not_active Expired - Fee Related
- 2012-11-09 CN CN201280065948.4A patent/CN104203247B/zh not_active Expired - Fee Related
- 2012-11-09 CN CN201280066021.2A patent/CN104185472B/zh not_active Expired - Fee Related
- 2012-11-09 SG SG11201402225RA patent/SG11201402225RA/en unknown
- 2012-11-09 MY MYPI2014001372A patent/MY182222A/en unknown
- 2012-11-09 EP EP12787337.0A patent/EP2776041A1/en not_active Withdrawn
- 2012-11-09 RU RU2014123471A patent/RU2683775C2/ru not_active IP Right Cessation
- 2012-11-09 IN IN3919CHN2014 patent/IN2014CN03919A/en unknown
- 2012-11-09 RU RU2014123472A patent/RU2688159C2/ru not_active IP Right Cessation
- 2012-11-09 WO PCT/US2012/064296 patent/WO2013071010A1/en active Application Filing
- 2012-11-09 ES ES12787336T patent/ES2806603T3/es active Active
- 2012-11-09 MY MYPI2014001373A patent/MY172227A/en unknown
- 2012-11-09 SG SG10201603766PA patent/SG10201603766PA/en unknown
- 2012-11-09 JP JP2014541292A patent/JP6216719B2/ja not_active Expired - Fee Related
- 2012-11-09 SG SG11201402247PA patent/SG11201402247PA/en unknown
- 2012-11-09 WO PCT/US2012/064293 patent/WO2013071009A1/en active Application Filing
- 2012-11-09 KR KR1020147015647A patent/KR102049615B1/ko active IP Right Grant
- 2012-11-09 AU AU2012335589A patent/AU2012335589B2/en not_active Ceased
- 2012-11-09 MX MX2014005679A patent/MX365859B/es active IP Right Grant
- 2012-11-09 KR KR1020147015650A patent/KR20140095549A/ko active IP Right Grant
- 2012-11-09 IN IN3903CHN2014 patent/IN2014CN03903A/en unknown
- 2012-11-09 EP EP12787336.2A patent/EP2776040B1/en active Active
- 2012-11-12 AR ARP120104261A patent/AR088846A1/es unknown
-
2014
- 2014-05-09 PH PH12014501078A patent/PH12014501078A1/en unknown
- 2014-05-09 MX MX2019006877A patent/MX2019006877A/es unknown
- 2014-05-09 PH PH12014501079A patent/PH12014501079B1/en unknown
- 2014-05-11 IL IL232535A patent/IL232535B/en active IP Right Grant
- 2014-05-11 IL IL232534A patent/IL232534A0/en active IP Right Grant
- 2014-05-12 CL CL2014001244A patent/CL2014001244A1/es unknown
- 2014-05-12 CL CL2014001243A patent/CL2014001243A1/es unknown
- 2014-05-13 ZA ZA2014/03431A patent/ZA201403431B/en unknown
- 2014-05-13 ZA ZA2014/03430A patent/ZA201403430B/en unknown
- 2014-05-29 CO CO14116546A patent/CO6970598A2/es unknown
- 2014-06-09 CO CO14124183A patent/CO6970609A2/es unknown
- 2014-09-12 US US14/485,335 patent/US9717743B2/en not_active Expired - Fee Related
- 2014-11-05 US US14/533,847 patent/US9433631B2/en active Active
-
2015
- 2015-01-31 HK HK15101081.1A patent/HK1200367A1/xx unknown
- 2015-01-31 HK HK15101080.2A patent/HK1200366A1/xx unknown
-
2016
- 2016-08-04 US US15/228,674 patent/US10493082B2/en not_active Expired - Fee Related
-
2017
- 2017-06-30 US US15/640,093 patent/US10188667B2/en not_active Expired - Fee Related
-
2018
- 2018-01-19 AU AU2018200436A patent/AU2018200436B2/en not_active Ceased
- 2018-12-24 US US16/231,901 patent/US20190365786A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014001244A1 (es) | Uso de una composicion farmaceutica que comprende un derivado de 4-pregenen-11beta-17-21-triol-3,20-diona para tratar una condicion ocular tal como presion intraocular elevada, glaucoma, uveitis, degeneracion macular, retinopatia diabetica, rosacea ocular, desprendimiento de retina, entre otras. | |
CR10041A (es) | Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares | |
CL2013002134A1 (es) | Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno. | |
BR112013008452A2 (pt) | composição e métodos de tratamento de edema ocular, neovascularização e doenças relacionadas | |
BR112014008759A8 (pt) | Tratamento de doença ocular | |
CL2013003042A1 (es) | Compuestos derivados metilamina de biciclos sustituidos, moduladores de receptores de esfingosin-1- fosfato; composicion farmaceutica; y un metodo de tratamiento para tratar enfermedades oculares, degeneracion macular, retinopatia, entre otros | |
MY171920A (en) | Prevention and treatment of ocular conditions | |
MX2016009331A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
CL2013000736A1 (es) | Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos. | |
CO2017005404A2 (es) | Anticuerpos contra il-6 | |
WO2008140052A1 (ja) | ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤 | |
MX360683B (es) | Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico. | |
BR112015006929A2 (pt) | sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas | |
IN2014CN03123A (es) | ||
AR062395A1 (es) | Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares | |
CL2015001187A1 (es) | Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades. | |
CL2012002612A1 (es) | Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma. | |
WO2012163827A3 (en) | Ophthalmic preparation comprising a pgf2alpha analogue | |
EP3238746A4 (en) | High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein | |
BR112014009761B8 (pt) | Composição de reticulação melhorada entregue por iontoforese, útil para o tratamento de ceratocone | |
MX2013001870A (es) | Formulaciones oftalmicas de escualamina. | |
BR112014010095A2 (pt) | tonômetro de aplanação e método para mediação da pressão intra ocular | |
CL2015001701A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, un hidrato, solvato o una sal de este, o un polimorfo del mismo y al menos un vehiculo; procedimiento para elaborarla; y procedimiento para tratar o impedir un trastorno oftalmologico seleccionado de retinitis pigmentosa, glaucoma y cataratas, entre otros. | |
BR112014020424A2 (pt) | ponta de fragmentação, dispositio de cirurgia intra-ocular fornecido com as mesmas, método para suprimir ocorrência de cavitação e método de cirurgia de catarata | |
WO2008124151A3 (en) | Use of creatine compounds for the treatment of eye disorders |